Here’s a breakdown of the key information from the provided text, focusing on the study details:
Study Focus:
* The study investigated the effectiveness of different doses of I-ACQUIRE treatment for children with arm weakness after stroke.
Treatment Groups & Dosage:
* high-Dose I-ACQUIRE: 120 hours of therapist-delivered treatment in the child’s home or a home-like setting.
* Moderate-dose I-ACQUIRE: 60 hours of therapist-delivered treatment in the child’s home or a home-like setting.
* Usual Care: An average of 2.2 hours of weekly therapy (typically one hour each with an occupational and physical therapist).
Delayed Treatment Option:
* Parents in the “usual care” group could enroll their children in a “delayed Treatment Study” to receive either moderate- or high-dose I-ACQUIRE after the initial six-month assessment.Assignment to moderate or high dose was random (1:1).
Study Oversight & Safety:
* The study was overseen by statisticians, a Data Safety and Monitoring Board, and an autonomous medical monitor.
* Adverse events were documented and addressed.
Funding:
* The study was funded by the National Institute of Neurological Disorders and Stroke (part of the National Institutes of Health).
Important Considerations (Disclaimers):
* The findings are preliminary as they were presented at a scientific meeting and haven’t yet been published in a peer-reviewed journal.
* The statements and conclusions are those of the study authors and don’t necessarily reflect the American Heart Association/American Stroke Association’s official position.
* The Association has policies to ensure donations don’t influence scientific content.
Keep reading